Literature DB >> 22100229

Loss of fibulin-2 protects against progressive ventricular dysfunction after myocardial infarction.

Takeshi Tsuda1, Jing Wu, Erhe Gao, Jennifer Joyce, Dessislava Markova, Hailong Dong, Ying Liu, Hangxiang Zhang, Yaqun Zou, Feng Gao, Thomas Miller, Walter Koch, Xingliang Ma, Mon-Li Chu.   

Abstract

Remodeling of the cardiac extracellular matrix (ECM) is an integral part of wound healing and ventricular adaptation after myocardial infarction (MI), but the underlying mechanisms remain incompletely understood. Fibulin-2 is an ECM protein upregulated during cardiac development and skin wound healing, yet mice lacking fibulin-2 do not display any identifiable phenotypic abnormalities. To investigate the effects of fibulin-2 deficiency on ECM remodeling after MI, we induced experimental MI by permanent coronary artery ligation in both fibulin-2 null and wild-type mice. Fibulin-2 expression was up-regulated at the infarct border zone of the wild-type mice. Acute myocardial tissue responses after MI, including inflammatory cell infiltration and ECM protein synthesis and deposition in the infarct border zone, were markedly attenuated in the fibulin-2 null mice. However, the fibulin-2 null mice had significantly better survival rate after MI compared to the wild-type mice as a result of less frequent cardiac rupture and preserved left ventricular function. Up-regulation of TGF-β signaling and ECM remodeling after MI were attenuated in both ischemic and non-ischemic myocardium of the fibulin-2 null mice compared to the wild type counterparts. Increase in TGF-β signaling in response to angiotensin II was also lessened in cardiac fibroblasts isolated from the fibulin-2 null mice. The studies provide the first evidence that absence of fibulin-2 results in decreased up-regulation of TGF-β signaling after MI and protects against ventricular dysfunction, suggesting that fibulin-2 may be a potential therapeutic target for attenuating the progression of ventricular remodeling.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22100229      PMCID: PMC3390264          DOI: 10.1016/j.yjmcc.2011.11.001

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  34 in total

1.  Genes expressed in human tumor endothelium.

Authors:  B St Croix; C Rago; V Velculescu; G Traverso; K E Romans; E Montgomery; A Lal; G J Riggins; C Lengauer; B Vogelstein; K W Kinzler
Journal:  Science       Date:  2000-08-18       Impact factor: 47.728

Review 2.  Fibulins: a versatile family of extracellular matrix proteins.

Authors:  Rupert Timpl; Takako Sasaki; Günter Kostka; Mon-Li Chu
Journal:  Nat Rev Mol Cell Biol       Date:  2003-06       Impact factor: 94.444

3.  Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction.

Authors:  Jack P M Cleutjens; Esther E J M Creemers
Journal:  J Card Fail       Date:  2002-12       Impact factor: 5.712

Review 4.  Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?

Authors:  Bodh I Jugdutt
Journal:  Circulation       Date:  2003-09-16       Impact factor: 29.690

5.  TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice.

Authors:  D Zhang; V Gaussin; G E Taffet; N S Belaguli; M Yamada; R J Schwartz; L H Michael; P A Overbeek; M D Schneider
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

6.  Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction.

Authors:  K Harada; T Sugaya; K Murakami; Y Yazaki; I Komuro
Journal:  Circulation       Date:  1999-11-16       Impact factor: 29.690

7.  Fibulin-2 expression marks transformed mesenchymal cells in developing cardiac valves, aortic arch vessels, and coronary vessels.

Authors:  T Tsuda; H Wang; R Timpl; M L Chu
Journal:  Dev Dyn       Date:  2001-09       Impact factor: 3.780

Review 8.  Induction of cardiac fibrosis by transforming growth factor-beta(1).

Authors:  P J Lijnen; V V Petrov; R H Fagard
Journal:  Mol Genet Metab       Date:  2000 Sep-Oct       Impact factor: 4.797

9.  Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction.

Authors:  Shunji Hayashidani; Hiroyuki Tsutsui; Masaki Ikeuchi; Tetsuya Shiomi; Hidenori Matsusaka; Toru Kubota; Kyoko Imanaka-Yoshida; Takeshi Itoh; Akira Takeshita
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-29       Impact factor: 4.733

Review 10.  The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction.

Authors:  Marcin Dobaczewski; Carlos Gonzalez-Quesada; Nikolaos G Frangogiannis
Journal:  J Mol Cell Cardiol       Date:  2009-07-23       Impact factor: 5.000

View more
  15 in total

1.  The expression level of fibulin-2 in the circulating RNA (ctRNA) of epithelial tumor cells of peripheral blood and tumor tissue of patients with metastatic lung cancer.

Authors:  Mukaddes Avsar; Makbule Tambas; Zubeyde Yalniz; Demet Akdeniz; Seref Bugra Tuncer; Seda Kilic; Ozge Sukruoglu Erdogan; Rumeysa Ciftci; Nergiz Dagoglu; Sezai Vatansever; Hulya Yazici
Journal:  Mol Biol Rep       Date:  2019-05-08       Impact factor: 2.316

2.  Validation of diagnostic criteria and histopathological characterization of cardiac rupture in the mouse model of nonreperfused myocardial infarction.

Authors:  Anis Hanna; Arti V Shinde; Nikolaos G Frangogiannis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-09-04       Impact factor: 4.733

Review 3.  The therapeutic potential of miRNAs in cardiac fibrosis: where do we stand?

Authors:  Wino J Wijnen; Yigal M Pinto; Esther E Creemers
Journal:  J Cardiovasc Transl Res       Date:  2013-07-03       Impact factor: 4.132

Review 4.  Matrix control of transforming growth factor-β function.

Authors:  Masahito Horiguchi; Mitsuhiko Ota; Daniel B Rifkin
Journal:  J Biochem       Date:  2012-08-24       Impact factor: 3.387

5.  Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor-β signalling.

Authors:  Hangxiang Zhang; Jing Wu; Hailong Dong; Shaukat A Khan; Mon-Li Chu; Takeshi Tsuda
Journal:  Clin Sci (Lond)       Date:  2014-02       Impact factor: 6.124

6.  Fibulin 2, a tyrosine O-sulfated protein, is up-regulated following retinal detachment.

Authors:  Yogita Kanan; Daniel Brobst; Zongchao Han; Muna I Naash; Muayyad R Al-Ubaidi
Journal:  J Biol Chem       Date:  2014-04-01       Impact factor: 5.157

Review 7.  Systems biology-opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix.

Authors:  Javier Barallobre-Barreiro; Marc Lynch; Xiaoke Yin; Manuel Mayr
Journal:  Cardiovasc Res       Date:  2016-09-15       Impact factor: 10.787

8.  Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling.

Authors:  Ioannis Karakikes; Antoine H Chaanine; Soojeong Kang; Bertrand N Mukete; Dongtak Jeong; Shihong Zhang; Roger J Hajjar; Djamel Lebeche
Journal:  J Am Heart Assoc       Date:  2013-04-23       Impact factor: 5.501

9.  Fibulin-2 is a driver of malignant progression in lung adenocarcinoma.

Authors:  Brandi N Baird; Mark J Schliekelman; Young-Ho Ahn; Yulong Chen; Jonathon D Roybal; Bartley J Gill; Dhruva K Mishra; Baruch Erez; Michael O'Reilly; Yanan Yang; Mayuri Patel; Xin Liu; Nishan Thilaganathan; Irina V Larina; Mary E Dickinson; Jennifer L West; Don L Gibbons; Diane D Liu; Min P Kim; John M Hicks; Ignacio I Wistuba; Samir M Hanash; Jonathan M Kurie
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

10.  Fibulin-2 is essential for angiotensin II-induced myocardial fibrosis mediated by transforming growth factor (TGF)-β.

Authors:  Shaukat A Khan; Hailong Dong; Jennifer Joyce; Takako Sasaki; Mon-Li Chu; Takeshi Tsuda
Journal:  Lab Invest       Date:  2016-04-25       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.